Literature DB >> 21660476

[Pathological work-up of rectal cancer following partial/total mesorectal excision].

K J Schmitz1, C Chmelar, E Berg, K W Schmid.   

Abstract

Total mesorectal excision (TME) refers to the anatomically accurate surgical resection of the rectum from its surrounding fascias and has become the gold standard for treating rectal cancer. The pathologist plays a key role in the assessment of these specimens and good pathological reporting of rectal cancer is essential to achieving the optimum possible results for patients with rectal cancer. In experienced hands, these techniques result in a dramatic improvement in cancer-related cure rates from 45% to 75% and a reduction in pelvic recurrences from 40% to 5%-10%. Moreover, preservation of sexual and urinary functions is possible in the majority of cases. This article reviews the pathological assessment of the TME specimen in detail with regards to current international guidelines and describes its anatomical background. In addition, particular issues relating to margins, lymph node dissection and effects of neoadjuvant therapy are discussed.

Entities:  

Mesh:

Year:  2011        PMID: 21660476     DOI: 10.1007/s00292-011-1439-x

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  26 in total

1.  Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage.

Authors:  N S Goldstein; A Soman; J Sacksner
Journal:  Am J Clin Pathol       Date:  1999-03       Impact factor: 2.493

2.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

Review 3.  [Update S3-guideline "colorectal cancer" 2008].

Authors:  W Schmiegel; A Reinacher-Schick; D Arnold; U Graeven; V Heinemann; R Porschen; J Riemann; C Rödel; R Sauer; M Wieser; W Schmitt; H-J Schmoll; T Seufferlein; I Kopp; C Pox
Journal:  Z Gastroenterol       Date:  2008-08       Impact factor: 2.000

4.  [Methods for postoperative evaluation of complete excision of the mesorectum].

Authors:  P Sterk; T Nagel; S Günter; F Schubert; P Klein
Journal:  Zentralbl Chir       Date:  2000       Impact factor: 0.942

5.  Fewer than 12 lymph nodes can be expected in a surgical specimen after high-dose chemoradiation therapy for rectal cancer.

Authors:  J H Marks; E B Valsdottir; A A Rather; I C Nweze; D A Newman; M R Chernick
Journal:  Dis Colon Rectum       Date:  2010-07       Impact factor: 4.585

6.  Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.

Authors:  Nam Kyu Kim; Seung Hyuk Baik; Jin Sil Seong; Hoguen Kim; Jae Kyung Roh; Kang Young Lee; Seung Kook Sohn; Chang Hwan Cho
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

7.  Lymph node yield in rectal cancer surgery: effect of preoperative chemoradiotherapy.

Authors:  B Morcos; B Baker; M Al Masri; H Haddad; S Hashem
Journal:  Eur J Surg Oncol       Date:  2010-01-13       Impact factor: 4.424

8.  Clearance technique for the detection of lymph nodes in colorectal cancer.

Authors:  S J Cawthorn; N M Gibbs; C G Marks
Journal:  Br J Surg       Date:  1986-01       Impact factor: 6.939

9.  Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer.

Authors:  Nicholas P West; Paul J Finan; Claes Anderin; Johan Lindholm; Torbjorn Holm; Philip Quirke
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

View more
  1 in total

Review 1.  [Pathology of the R1 classification in visceral cancer surgery].

Authors:  M J Pollheimer; C Langner
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.